HighTower Advisors LLC Grows Stake in Fresenius Medical Care AG (NYSE:FMS)

HighTower Advisors LLC increased its holdings in shares of Fresenius Medical Care AG (NYSE:FMS) by 7.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,890 shares of the company’s stock after acquiring an additional 1,305 shares during the quarter. HighTower Advisors LLC’s holdings in Fresenius Medical Care were worth $405,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC increased its position in shares of Fresenius Medical Care by 192.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company’s stock worth $28,000 after purchasing an additional 806 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Fresenius Medical Care during the third quarter worth about $38,000. Jones Financial Companies Lllp increased its holdings in shares of Fresenius Medical Care by 80.5% in the 4th quarter. Jones Financial Companies Lllp now owns 4,510 shares of the company’s stock valued at $102,000 after acquiring an additional 2,012 shares during the period. Venturi Wealth Management LLC grew its holdings in shares of Fresenius Medical Care by 8.4% during the fourth quarter. Venturi Wealth Management LLC now owns 5,700 shares of the company’s stock worth $129,000 after buying an additional 441 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in shares of Fresenius Medical Care by 43.3% in the 4th quarter. GAMMA Investing LLC now owns 7,164 shares of the company’s stock worth $162,000 after acquiring an additional 2,166 shares during the period. Hedge funds and other institutional investors own 8.37% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Truist Financial upped their target price on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. Bank of America raised Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. Finally, StockNews.com upgraded shares of Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th.

Fresenius Medical Care Stock Performance

Shares of FMS opened at $24.94 on Tuesday. The stock has a market capitalization of $14.64 billion, a PE ratio of 20.61, a price-to-earnings-growth ratio of 0.76 and a beta of 0.99. Fresenius Medical Care AG has a 12-month low of $17.93 and a 12-month high of $25.25. The business’s fifty day moving average price is $24.06 and its 200 day moving average price is $22.57. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.